HTA frameworks for RA therapies need improvement, researchers say

13 May 2019 - Cost-effectiveness models for the treatment of rheumatoid arthritis first emerged in the early 2000s when highly effective ...

Read more →

Australia's GBMA launches hub for biosimilar education

13 May 2019 - In 2018, the Generic Biosimilar Medicines Association was awarded the Biosimilar Education Grant by the Australian government ...

Read more →

Statement from Acting FDA Commissioner on policy advancements to help bring interchangeable biosimilars to market

10 May 2019 - The U.S. FDA plays an important role in helping to address the high cost of medicines ...

Read more →

Evolus receives positive CHMP opinion for Nuceiva in the European Union

26 April 2019 - European Commission approval anticipated within 90 days. ...

Read more →

FDA approves Samsung Bioepis' etanercept biosimilar, Eticovo

26 April 2019 - The FDA has approved Samsung Bioepis’ etanercept biosimilar, SB4, as Eticovo (etanercept-ykro). ...

Read more →

Bach, co-authors call for regulated pricing for biologics as an alternative to biosimilars

15 April 2019 - The 2 part proposal from Peter B. Bach and 3 co-authors published Monday argues that biosimilar competition ...

Read more →

Biopharma CEOs explain problems with biosimilars to Congress

12 April 2019 - Following their Senate Finance Committee hearing in February, all seven biopharmaceutical CEOs have now offered hundreds ...

Read more →

Teva Canada announces the approval of Truxima, the first biosimilar to Rituxan in Canada for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukaemia and rheumatoid arthritis

10 April 2019 - Teva Canada announces that Health Canada has granted a notice of compliance  for Truxima (rituximab), the ...

Read more →

Biosimilars are a distraction

8 April 2019 - Biopharmaceutical products (also known as biologics) are among the most expensive pharmaceutical products on the market, and ...

Read more →

Fresenius Kabi receives European Commission approval for adalimumab biosimilar Idacio

3 April 2019 - The European Commission granted Fresenius Kabi the marketing authorization for Idacio, an adalimumab biosimilar, for all indications ...

Read more →

AbbVie's massive Humira discounts are stifling Netherlands biosimilars

2 April 2019 - Could a drug's price ever be too low? That’s what some market-watchers are asking in the ...

Read more →

Sandoz resubmits biosimilar pegfilgrastim application to US FDA

2 April 2019 - Sandoz pursues US approval for biosimilar pegfilgrastim, a long-acting version of supportive oncology medicine filgrastim. ...

Read more →

One Canadian payer's experience with biosimilars

25 March 2019 - Much of the discussion about biosimilar uptake revolves around challenges in the United States, but other ...

Read more →

Promoting biosimilars up to health plans, manufacturers, doctors, Gottlieb says

21 March 2019 - As he wraps up his final weeks as commissioner of the FDA, Scott Gottlieb, MD, talked about ...

Read more →

AbbVie is sued for using Humira patent deals to block competition in the U.S.

20 March 2019 - In a novel step, a New York union accused AbbVie and seven other drug makers of ...

Read more →